The miRoncol Real-time Multi-Cancer Early Risk Assessment model was studied rigorously based on large sets of cancer patients and healthy controls. Results demonstrate high accuracy across multiple solid tumour types, providing meaningful early insight that complements physician-led care with peer reviewed publications.
For an early risk assessment tool to be valuable, it must:
miRoncol has been designed and validated with these principles at its core.
*Our current test does not detect Breast cancer accurately. People with breast cancer can still get a positive signal. The sensitivity is not as high as other common solid tumors we have studied.
Studies included cancers that represent the majority of cases seen in Canada and worldwide, including:
The scientific foundation of miRoncol’s test has been published in respected journals:
While accuracy is high, no test is perfect, and results should always be interpreted with care. A positive result signals that certain molecular patterns have been detected it does not mean cancer is present, but rather that follow-up with your physician may be helpful.
Likewise, a negative result means no cancer-linked patterns were detected at this time, but it does not replace conventional screenings or ongoing prevention. The test is designed to add meaningful, real-time insight that complements existing medical evaluations.
miRoncol is currenting conducting studies before launching the first version of its test in 2026 Canada wide.
Be among the first to access real-time multi-cancer risk assessment for your health and prevention plan
Read the peer-reviewed research behind miRoncol’s innovative approach
Be among the first clinics to bring real-time multi-cancer risk assessment to your patients and set a new standard in preventive care
Stay ahead in employee wellness by offering cutting-edge cancer risk assessment as part of your health and benefits strategy